Acadia accelerates ACP-103 phase 2 schizophrenia trial

By Elaine Rigoli

Tampa, Fla., Sept. 25 - Acadia Pharmaceuticals, Inc. said the timing of its phase 2 adjunctive therapy trial with ACP-103 in patients with schizophrenia is significantly ahead of schedule, which should enable the company to report top-line results for the complete 400-patient clinical trial during the first quarter of 2007, ahead of earlier expectations.

Given the rapid enrollment and opportunity to expedite results for the complete study, the San Diego-based biopharmaceutical company said it will no longer perform an interim analysis based on the first 200 patients, which had been planned to be conducted by the end of 2006.

The phase 2 clinical trial is a multi-center, double-blind, placebo-controlled study designed to evaluate the ability of ACP-103 when used adjunctively with each of risperidone, an atypical antipsychotic drug, and haloperidol, a typical antipsychotic drug, to provide an improved therapy for patients with schizophrenia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.